← Analyst Upside
AU · rank #2 · 2026-07-22
NUTX
NASDAQ · $1.12B (USD)
SignalHold
verdict · CAUTION
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 3.015 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.58 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.197 |
| Analyst upside Consensus target $246.40 | +46.4% |
| Momentum acceleration 3-month minus 12-month momentum. | +36.89% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.67 |
| Gross margin TTM | +50.6% |
| 52w high | $204.00 |
| Market cap (USD) | $1.12B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Nutex Health (NUTX) runs a physician-led network of micro-hospitals and hospital outpatient departments plus a population health business across 12 states.
Rationale
The quant case is reinforced by strong analyst support, a 46.4% target upside, 100% revision agreement, and upward EPS revisions alongside a solid Q1 beat with improved cash generation.
Material risks
- 1Analyst targets are still highly dispersed at 50.7%, so the upside signal is less reliable if the market loses confidence in the earnings trajectory.
- 2Reported earnings are being helped by No Surprises Act arbitration timing, making near-term results and revisions vulnerable to volatility if reimbursement timing normalizes.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.
OpenAI
Proceed
Claude
Caution
Gemini
Error